CURR vs. OPRX, PHLT, TCX, RGP, PESI, OABI, RCMT, PAYS, EPWK, and JUNE
Should you be buying CURRENC Group stock or one of its competitors? The main competitors of CURRENC Group include OptimizeRx (OPRX), Performant Healthcare, Inc. - Common Stock (PHLT), Tucows (TCX), Resources Connection (RGP), Perma-Fix Environmental Services (PESI), OmniAb (OABI), RCM Technologies (RCMT), Paysign (PAYS), EPWK (EPWK), and Junee (JUNE). These companies are all part of the "business services" industry.
CURRENC Group vs.
OptimizeRx (NASDAQ:OPRX) and CURRENC Group (NASDAQ:CURR) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 56.0% of CURRENC Group shares are held by institutional investors. 5.6% of OptimizeRx shares are held by company insiders. Comparatively, 17.8% of CURRENC Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, OptimizeRx had 1 more articles in the media than CURRENC Group. MarketBeat recorded 4 mentions for OptimizeRx and 3 mentions for CURRENC Group. OptimizeRx's average media sentiment score of 1.28 beat CURRENC Group's score of -0.75 indicating that OptimizeRx is being referred to more favorably in the media.
CURRENC Group has lower revenue, but higher earnings than OptimizeRx.
OptimizeRx received 160 more outperform votes than CURRENC Group when rated by MarketBeat users. However, 66.67% of users gave CURRENC Group an outperform vote while only 64.80% of users gave OptimizeRx an outperform vote.
CURRENC Group has a net margin of 0.00% compared to OptimizeRx's net margin of -27.41%. CURRENC Group's return on equity of 0.00% beat OptimizeRx's return on equity.
OptimizeRx has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, CURRENC Group has a beta of -0.17, meaning that its share price is 117% less volatile than the S&P 500.
OptimizeRx currently has a consensus price target of $10.38, indicating a potential downside of 10.64%. CURRENC Group has a consensus price target of $3.50, indicating a potential upside of 570.24%. Given CURRENC Group's stronger consensus rating and higher possible upside, analysts clearly believe CURRENC Group is more favorable than OptimizeRx.
Summary
OptimizeRx and CURRENC Group tied by winning 8 of the 16 factors compared between the two stocks.
Get CURRENC Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CURR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CURRENC Group Competitors List
Related Companies and Tools
This page (NASDAQ:CURR) was last updated on 5/22/2025 by MarketBeat.com Staff
